Analytical Study of Beneficial Effects of Magnesium Sulfate for the Neuroprotection in Pre-Term Babies in Tertiary Care Hospital Bahawalpur: Magnesium Sulfate for the Neuroprotection

Shabana Bibi; Syeda Uzma; Rabia Sajjad; Sadia Zainab Chaudhary; Viqar Ashraf; Sadaf Moin

doi:10.54393/pjhs.v6i5.2726

Authors

Shabana Bibi Department of Gynecology and Obstetrics, Combined Military Hospital, Bahawalpur, Pakistan
Syeda Uzma Department of Gynecology and Obstetrics, Combined Military Hospital, Bahawalpur, Pakistan
Rabia Sajjad Department of Gynecology and Obstetrics, Combined Military Hospital, Lahore, Pakistan
Sadia Zainab Chaudhary Department of Gynecology and Obstetrics, Combined Military Hospital, Bahawalpur, Pakistan
Viqar Ashraf Department of Gynecology and Obstetrics, Pakistan Emirates Military Hospital, Rawalpindi, Pakistan
Sadaf Moin Department of Gynecology and Obstetrics, Combined Military Hospital, Abbottabad, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i5.2726

Keywords:

Magnesium, Neuroprotection, Preterm Birth, Cerebral Palsy

Abstract

Neonatal morbidity and mortality are greatly influenced by preterm birth. Magnesium sulfate (MgSO4) has been suggested as a neuroprotective therapy to reduce the negative consequences on neurodevelopment in preterm infants. Objective: To investigate how MgSO4 works to reduce the incidence of cerebral palsy as well as other neurodevelopmental impairments in preterm infants. Methods: This quasi experimental study was conducted at Tertiary Care Hospital Bahawalpur in the Department of Obstetrics and Gynecology from September 30, 2022 to March 29, 2023. This research involved 312 preterm infants. The infants were divided to a group of treatment with MgSO4 or compared with a group without MgSO4 exposure. The incidence of intraventricular hemorrhage (IVH), need for mechanical ventilation, neonatal mortality, as well as cerebral palsy were also measured and compared between the groups using Chi-square and T-tests. Results: The administration of MgSO4, dramatically reduced the rate of IVH (6.4%, 16%, p = 0.007 respectively treatment and control group) and neonatal mortality (3.2%, 10.3%, p = .013). It did not significantly affect the need for mechanical ventilation. This proved to be effective in reducing cerebral palsy by 21.8 percentage points (4.5% vs 26.3%, p<0.001). Conclusion: MgSO4 administration antenatally greatly decreases the risks of IVH and neonatal mortality while decreasing the incidence of cerebral palsy in preterm infants, thereby resulting more to be a 'gold standard' neuroprotective strategy in prenatal care.

References

Jafarabady K, Shafiee A, Eshraghi N, Salehi SA, Mohammadi I, Rajai S et al. Magnesium sulfate for fetal neuroprotection in preterm pregnancy: a meta-analysis of randomized controlled trials. BioMed Central Pregnancy and Childbirth. 2024 Aug; 24(1): 519. doi: 10.1186/s12884-024-06703-9. DOI: https://doi.org/10.1186/s12884-024-06703-9

Bachnas MA, Akbar MI, Dachlan EG, Dekker G. The role of magnesium sulfate (MgSO4) in fetal neuroprotection. The Journal of Maternal-Fetal & Neonatal Medicine. 2021 Mar; 34(6): 966-78. doi: 10.1080/14767058.2019.1619688. DOI: https://doi.org/10.1080/14767058.2019.1619688

Magee L, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane JM et al. RETIRED: Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011 May; 33(5): 516-29. doi: 10.1016/S1701-2163(16)34886-1. DOI: https://doi.org/10.1016/S1701-2163(16)34886-1

Gupta N, Garg R, Gupta A, Mishra S. Magnesium sulfate for fetal neuroprotection in women at risk of preterm birth: analysis of its effect on cerebral palsy. Journal of South Asian Federation of Obstetrics and Gynaecology. 2021 May; 13(3): 91. doi: 10.5005/jp-journals-10006-1907. DOI: https://doi.org/10.5005/jp-journals-10006-1907

Oddie S, Tuffnell DJ, McGuire W. Antenatal magnesium sulfate: neuro-protection for preterm infants. Archives of Disease in Childhood-Fetal and Neonatal Edition. 2015 Nov; 100(6): F553-7. doi: 10.1136/archdischild-2014-307655. DOI: https://doi.org/10.1136/archdischild-2014-307655

Hurrion EM, Badawi N, Boyd RN, Morgan C, Gibbons K, Hennig S et al. SuPreme Study: a protocol to study the neuroprotective potential of sulfate among very/extremely preterm infants. British Medical Journal Open. 2023 Jul; 13(7): e076130. doi: 10.1136/bmjopen-2023-076130. DOI: https://doi.org/10.1136/bmjopen-2023-076130

Millochau JC, Marret S, Oden S, Verspyck E. État des lieux de l'utilisation du sulfate de magnésium à visée neuroprotectrice au CHU de Rouen. Gynécologie Obstétrique & Fertilité. 2016 Jul; 44(7-8): 446-9. doi: 10.1016/j.gyobfe.2016.05.008. DOI: https://doi.org/10.1016/j.gyobfe.2016.05.008

Jayaram PM, Mohan MK, Farid I, Lindow S. Antenatal magnesium sulfate for fetal neuroprotection: a critical appraisal and systematic review of clinical practice guidelines. Journal of Perinatal Medicine. 2019 Apr; 47(3): 262-9. doi: 10.1515/jpm-2018-0174. DOI: https://doi.org/10.1515/jpm-2018-0174

Tsakiridis I, Mamopoulos A, Athanasiadis A, Dagklis T. Antenatal corticosteroids and magnesium sulfate for improved preterm neonatal outcomes: a review of guidelines. Obstetrical & Gynecological Survey. 2020 May; 75(5): 298-307. doi: 10.1097/OGX.0000000000000778. DOI: https://doi.org/10.1097/OGX.0000000000000778

Jonsdotter A, Rocha‐Ferreira E, Hagberg H, Carlsson Y. Maternal and fetal serum concentrations of magnesium after administration of a 6‐g bolus dose of magnesium sulfate (MgSO4) to women with imminent preterm delivery. Acta Obstetricia et Gynecologica Scandinavica. 2022 Aug; 101(8): 856-61. doi: 10.1111/aogs.14372. DOI: https://doi.org/10.1111/aogs.14372

Omori-Shimano S, Tominaga T, Ikeda K. Maternal magnesium sulfate administration increases early-onset hyperkalemia risk in premature infants: A propensity score-matched, case-control study. Pediatrics & Neonatology. 2023 Mar; 64(2): 119-25. doi: 10.1016/j.pedneo.2022.06.011. DOI: https://doi.org/10.1016/j.pedneo.2022.06.011

Tominaga T, Ikeda K, Awazu M. Transient hypercalcemia followed by hypocalcemia in a preterm infant after maternal magnesium sulfate therapy. Clinical Pediatric Endocrinology. 2022; 31(2): 77-80. doi: 10.1297/cpe.2021-0061. DOI: https://doi.org/10.1297/cpe.2021-0061

Kim SH, Kim YJ, Shin SH, Cho H, Shin SH, Kim EK et al. Antenatal magnesium sulfate and intestinal morbidities in preterm infants with extremely low gestational age. Pediatrics & Neonatology. 2021 Mar; 62(2): 202-7. doi: 10.1016/j.pedneo.2020.12.009. DOI: https://doi.org/10.1016/j.pedneo.2020.12.009

Bansal V and Desai A. Efficacy of antenatal magnesium sulfate for neuroprotection in extreme prematurity: a comparative observational study. The Journal of Obstetrics and Gynecology of India. 2021 Dec: 1-2. doi: 10.1007/s13224-021-01531-9. DOI: https://doi.org/10.1007/s13224-021-01531-9

Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Developmental Medicine & Child Neurology. 2000 Dec; 42(12): 816-24. doi: 10.1111/j.1469-8749.2000.tb00695.x. DOI: https://doi.org/10.1111/j.1469-8749.2000.tb00695.x

Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. The Journal of Pediatrics. 1978 Apr; 92(4): 529-34. doi: 10.1016/S0022-3476(78)80282-0. DOI: https://doi.org/10.1016/S0022-3476(78)80282-0

Chollat C, Sentilhes L, Marret S. Fetal neuroprotection by magnesium sulfate: from translational research to clinical application. Frontiers in Neurology. 2018 Apr; 9: 247. doi: 10.3389/fneur.2018.00247. DOI: https://doi.org/10.3389/fneur.2018.00247

Monteagudo BF, Castro SV, García PC, Sarrato SZ, Luna MS. Neuroprotective effect of magnesium sulfate in premature infants. Analysis after establishing an antenatal administration protocol in a tertiary care hospital. Anales de Pediatría (English Edition). 2023 Oct; 99(4): 224-31. doi: 10.1016/j.anpede.2023.07.007. DOI: https://doi.org/10.1016/j.anpede.2023.07.007

Crowther CA, Middleton PF, Voysey M, Askie L, Duley L, Pryde PG et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLOS Medicine. 2017 Oct; 14(10): e1002398. doi: 10.1371/journal.pmed.1002398. DOI: https://doi.org/10.1371/journal.pmed.1002398

McLeod RM, Rosenkrantz TS, Fitch RH. Antenatal Magnesium Sulfate Benefits Female Preterm Infants but Results in Poor Male Outcomes. Pharmaceuticals. 2024 Feb; 17(2): 218. doi: 10.3390/ph17020218. DOI: https://doi.org/10.3390/ph17020218

Burhouse A, Lea C, Ray S, Bailey H, Davies R, Harding H et al. Preventing cerebral palsy in preterm labour: a multiorganisational quality improvement approach to the adoption and spread of magnesium sulphate for neuroprotection. British Medical Journal Open Quality. 2017 Oct; 6(2): e000189. doi: 10.1136/bmjoq-2017-000189. DOI: https://doi.org/10.1136/bmjoq-2017-000189

Ayed M, Ahmed J, More K, Ayed A, Husain H, AlQurashi A et al. Antenatal magnesium sulfate for preterm neuroprotection: a single-center experience from Kuwait Tertiary NICU. Biomedicine hub. 2022 Jun; 7(2): 80-7. doi: 10.1159/000525431. DOI: https://doi.org/10.1159/000525431